CARM — Carisma Therapeutics Balance Sheet
0.000.00%
- $10.43m
- -$6.55m
- $19.63m
- 32
- 41
- 22
- 22
Annual balance sheet for Carisma Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 52.4 | 163 | 167 | 77.6 | 17.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 24.5 | 0.825 | — | 2.86 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 62.9 | 206 | 189 | 80.5 | 23.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.123 | 0.043 | 0 | 8.94 | 6.42 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 123 | 241 | 189 | 89.6 | 30.5 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18 | 11.6 | 31 | 15.9 | 16.1 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 132 | 69 | 31 | 63 | 58.4 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -9.23 | 172 | 158 | 26.5 | -27.9 |
Total Liabilities & Shareholders' Equity | 123 | 241 | 189 | 89.6 | 30.5 |
Total Common Shares Outstanding |